10x Genomics Reports Second Quarter 2026 Financial Results
10x Genomics (Nasdaq: TXG) reported Q2 2026 revenue of $151.0 million, down from $172.9 million in Q2 2025, and said excluding $1.6 million of patent settlement revenue, revenue rose 3% YoY. Gross margin was 74%. Operating loss was $19.6 million and net loss $17.9 million. It raised FY2026 revenue guidance to $610-$630 million.
How this was made
The 30-second read
Why it matters
The key tradable inputs are the Q2 financial results and the raised FY 2026 revenue guidance range, which can shift expectations for instrument and consumables demand and for margin trajectory.
Market read
Raised FY revenue guidance to $610M-$630M and reported Q2 margin improvement, but also showed operating and net losses with settlement-driven comparables.
What to watch
Operating expenses rose sharply year over year, and the revenue comparison is distorted by patent litigation settlement items; investors may discount the quality of growth until recurring license/royalty trends stabilize.
Background
10x Genomics is a single-cell and spatial biology platform company with instruments, consumables, and software, and it is actively expanding its multiomics and diagnostics strategy.
Ticker impact
10x Genomics reported Q2 2026 revenue of $151.0M, gross margin 74%, and raised full-year 2026 revenue guidance to $610M-$630M.
Likely positive bias into the after-hours call, with volatility driven by how investors interpret operating loss versus guidance and Atera order flow.
The article discloses a concrete guidance increase and Q2 financial metrics, but also shows operating loss and net loss, and several line items are influenced by non-recurring settlement revenue/gains.
Market effects
Single-cell and spatial tools peers may see read-across demand signals, especially if Atera order flow indicates improving instrument/consumables traction.
Limited direct regional spillover; primarily US biotech/life-science tools sentiment.
Moderate, as multiomics and diagnostics collaborations can influence broader research spending expectations.
Counterpoint
The guidance raise is modest and the quarter includes meaningful non-recurring settlement effects; operating loss widened, so the market may focus on cash burn and expense growth rather than top-line.
Key entities
- company10x Genomics, Inc.
Reported Q2 2026 results and raised full-year 2026 revenue guidance; highlighted Atera customer response and multi-year collaborations.
- product/platformAtera
Management cited extraordinary customer response and strong early order flow during the quarter.
- collaboration partnerCleveland Clinic
Announced multi-year research collaboration to advance diagnostic applications of single cell and spatial technologies.
- collaboration partnerLausanne University Hospital
Announced multi-year research collaboration to advance diagnostic applications of single cell and spatial technologies.
- acquisitionProteintech Genomics (Proteintech Group division)
Acquired Proteintech Genomics division to add advanced protein detection capabilities to 10x platforms.
